Loading
Every dated change on the records linked to Non-muscle-invasive bladder cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Pembrolizumab produced complete responses in a substantial minority of patients with BCG-unresponsive carcinoma in situ, about half of them lasting a year or more; approved in January 2020.
A milestone in how this cancer is treated.